TARRYTOWN, N.Y., May 1 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. will hold a teleconference to discuss its 2006 first quarter financial results on Friday, May 5, 2006, beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific). A replay of the call will be accessible approximately two hours following the end of the call and will be archived through May 12, 2006.
The live conference call dial-in number is: 1-800-819-9193 (U.S./Canada) 1-913-981-4911 (International) The live conference call ID number is: 6454497 To access a replay of the call: 1-888-203-1112 (U.S./Canada) 1-719-457-0820 (International) Conference replay PIN number is: 8928240
Emisphere will simultaneously be webcasting this teleconference. To access the live broadcast in listen-only mode or the subsequently archived recording, please go to the Investor Relations portion of the Company’s website at: http://www.emisphere.com/ir.asp.
Please visit the site at least five minutes prior to start time for instructions.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere’s business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere’s eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, heparin, insulin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world-leading pharmaceutical companies. For further information, please visit http://www.emisphere.com.
Emisphere Technologies, Inc.
CONTACT: Elliot M. Maza, CPA, J.D., Chief Financial Officer, EmisphereTechnologies, Inc., +1-914-785-4703; Media: Dan Budwick, BMCCommunications, +1-212-477-9007, ext. 14
